The Warsaw-based developer of mRNA vaccines and therapeutics ExPLoRNA Therapeutics has received $800,000 in funding from Bill & Melinda Gates Foundation.
- Established in 2019, ExploRNA Therapeutics develops mRNA therapeutics intended for anti-cancer applications and vaccinations. The solution developed by modifying a cap structure that stabilizes mRNA and significantly increases its translation efficiency, enabling the medical and health community to stimulate the development of an adaptive immune response to improve treatment outcomes.
- ExPLoRNA received funding from American private foundation Bill & Melinda Gates Foundation, the second-largest charitable foundation in the world. The foundation enhances healthcare industry, reduces extreme poverty across the world, expands educational opportunities and information technology in the US.
“We are grateful for the foundation’s support to help us achieve our vision. With the help of this grant, we intend to speed up the development of future mRNA vaccines and therapies,”
comments Jacek Jemielity, CEO of ExPLoRNA Therapeutics, and professor at the University of Warsaw.
- The funding will be used for a 14-month project to better understand the benefits of ExPLoRNA’s cap analogs, especially in terms of reducing the mRNA doses needed for therapeutic effects in the settings of vaccination and monoclonal antibody production.
